---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-047623"
form_type: "8-K"
ticker: "NRXS"
cik: "0001933567"
company_name: "Neuraxis, INC"
filed_at: "2024-11-25T23:59:59+00:00"
generated_at: "2026-05-29T19:11:47.940064+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Neuraxis appoints Dr. Gil Aharon to board effective Jan 1, 2025

## Summary
- Dr. Gil Aharon appointed to Neuraxis board effective Jan 1, 2025, as designee of investors in recent $5M Series B financing.
- Dr. Aharon co-founded Rosalind Advisors and purchased $250,000 of Series B Convertible Preferred Stock in the transaction.
- He has not yet been assigned to any board committee; director compensation is undetermined.
- No family relationships with other directors or officers; no other material interests in related-party transactions.

## SEC filing metadata
- accession: 0001493152-24-047623
- form_type: 8-K
- ticker: NRXS
- cik: 0001933567
- company_name: Neuraxis, INC
- filed_at: 2024-11-25T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1933567/000149315224047623/0001493152-24-047623-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1933567/000149315224047623/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-047623
- JSON: https://secwatch.observer/filing/0001493152-24-047623.json
- Plain text: https://secwatch.observer/filing/0001493152-24-047623.txt

## Key facts
- Executive change
  Dr. Gil Aharon was appointed as Director at Neuraxis, INC.
  - Action: appointed
  - Role: Director
  source text: the Board appointed Dr. Aharon to the Board, effective January 1, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1933567/000149315224047623/0001493152-24-047623-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.